Clinical trial · Interventional
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma
Tryptophan-kynurenine Pathway PET Imaging in Human Gliomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to evaluate Positron emission tomography/computed tomography (PET/CT) imaging with the radiotracer 1-(2-\[18F\]fluoroethyl)-l-tryptophan (\[18F\]FETrp) in patients diagnosed with a glioma. This study has 3 aims: * to assess if the \[18F\]FETrp PET/CT can outperform Magnetic Resonance Imaging (MRI) by providing a better treatment target volume in newly diagnosed Stage 4 glioma patients * better differentiate tumor progression from radiation induced MRI changes in post treatment stage 4 gliomas * by giving a drug that can inhibit a pathway to allow objective assessment of treatment effects in low grade gliomas
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Low Grade Glioma | Low Grade Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]FETrp PET/CT | Diagnostic Test | — | UNRESOLVED |
| Minocycline 200mg/day | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- [18F]FETrp PET/CT in newly diagnosed grade 4 glioma prior to radiation
- description
- Arm 1. \[18F\]FETrp PET prior to radiotherapy in newly diagnosed grade 4 glioblastoma to provide a better treatment target volume
- interventionNames
- Diagnostic Test: [18F]FETrp PET/CT
- type
- EXPERIMENTAL
- label
- [18F]FETrp PET/CT in previously treated gliomas with post radiation progression
- description
- Arm 2. \[18F\]FETrp PET to differentiate post-treatment glioma progression from radiation-induced MRI changes
- interventionNames
- Diagnostic Test: [18F]FETrp PET/CT
- type
- EXPERIMENTAL
- label
- [18F]FETrp PET/CT pre and post Minocycline 200mg/day
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
FOR ARMS 1-3 Inclusion Criteria: * Age =18 years. * Patient is able to lie in the PET/CT scanner for at least 60 minutes while undergoing scanning. * Patient is willing and able to review, understand, and provide written consent for the study procedures and indicates that they are aware of the investigational nature of this study. Exclusion Criteria: * Patients who are pregnant or lactating are excluded. Premenopausal women (defined per institutional guidelines) must have a negative pregnancy test (urine or serum) within 7 days of the PET scan. * Severe increased intracranial pressure, status epilepticus, or other severe or progressing clinical symptoms requiring urgent intervention in the opinion of the treating * Karnofsky performance score \<60, as determined by one of the clinician co- investigators. ADDITIONAL CRITERIA FOR ARM 1: Inclusion Criteria: * Histopathology/cytopathological diagnosis of a glioblastoma without a history of radiation. * The tumor is deemed amenable for radiation treatment (pre-radiation planning MRI can be done before or after the PET scan). ADDITIONAL CRITERIA FOR ARM 2: Inclusion Criteria: * Previous histopathology/cytopathological diagnosis of glioblastoma. * History of glioma radiation. * Presence of a new or progressing enhancing brain lesion on follow-up clinical MRI suspicious for post-radiation glioma progression or late radiation-induced MRI changes (i.e., radiation injury), at least 7 mm in bidirectional diameter. * The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks of the planned PET scan. ADDITIONAL CRITERIA FOR ARM 3 Inclusion Criteria: * MRI diagnosis of a brain tumor, previously verified to be a low-grade (WHO grade 2, IDH (isocitrate dehydrogenase) mutant glioma, based on histopathology from biopsy or resection. * The detected mass on the most recent clinical MRI is at least 7 mm in bidirectional diameter (i.e., twice the PET scanner resolution). * The tumor does not require urgent (within 1 month) resection, steroid treatment, or radiation. * The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks. * Patient agrees to have a baseline and follow-up PET/CT scan (approximately 1 month later) and interval oral treatment with 200mg/day minocycline. * Due to planned minocycline treatment, patients will need to have adequate renal function Exclusion Criteria: * Active connective tissue disorders, such as lupus or scleroderma. * History of allergic reaction to minocycline or any tetracyclines. * Ongoing treatment with warfarin with INR \> 1.5. * History of colitis during antibiotics treatment.
References
Publications (0)
Data not yet available